Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 415-430-8 | CAS number: 86403-32-9 CYASORB UV-3853 LIGHT STABILIZER; DASTIB 845; SANDUVOR 845
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Expert statement: 'Reaction mass of 2,2,6,6-tetramethylpiperidin-4-yl-hexadecanoate and 2,2,6,6-tetramethylpiperidin-4-yl-octadecanoate' has no potential for bioaccumulation. The relevant absorption rates can be estimated by expert judgement to 80% (oral, including metabolites and hydrolysis products), 30% (dermal) and 30% (inhalation).
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 80
- Absorption rate - dermal (%):
- 30
- Absorption rate - inhalation (%):
- 30
Additional information
In order to assess the toxicokinetic behaviour of SABOSTAB UV-91, the available toxicological and physico-chemical data were evaluated.
The substance, i.e. the unchanged parent compound, is expected to be rather poorly absorbed via the oral route. With a molecular weight of 395.67 g/mol resp. 423.73 g/mol, it is generally favourable for absorption. However, taking into account the Log Pow of > 6.5 (at 40°C and pH7), the absorption e.g. by diffusion might be hindered, and also, only water-soluble substances will readily dissolve into the gastrointestinal fluids and hence be available for absorption, which limits the absorption of the poorly soluble compound. Hence, an oral absorption rate of 25% or less can be estimated for the parent compound.
Based on the chemical structure of the substance and the results of the water solubility study, a hydrolysis of the parent compounds needs to be taken into account, which would lead to the formation of 2,2,6,6-Tetramethylpiperidin-4-ol and the fatty acids palmitic acid resp. stearic acid. The fatty acids are also regularly fed for nutrition and will be subjected to the naturally present process of the fatty acid metabolism. Consequently, these two substances do not need to be regarded further.The low molecular weight of 2,2,6,6-Tetramethylpiperidin-4-ol, its rather high water solubility and Log Pow of 0.94, however, make it very favourable for oral absorption.Taking the hydrolysis products also into account leads to the estimation of a precautionary absorption rate of approx. 80%, probably overestimating the actual oral absorption.
SABOSTAB UV-91 has a very low vapour pressure and a boiling point of 246°C at 39 kPa, clearly showing that the inhalative absorption as a gas does not have to be regarded, which is supported by its physical state, a waxy solid, which is not able to be inhaled. Thinking of a possible inhalation of an aerosol with the solved hydrolysis product 2,2,6,6-Tetramethylpiperidin-4-ol, however, a precautionary absorption rate of up to 30% can be estimated.
In case of SABOSTAB UV-91, neither an evaporation after skin contact nor very remarkable additional absorption-enhancing effects due to corrosivity need to be regarded. Taking into account its molecular weight, high Log Pow and low water solubility, a passage of the parent compound through the stratum corneum is unlikely. 2,2,6,6-Tetramethylpiperidin-4-ol, on the other hand, has a molecular weight of 157.25, a high water solubility (> 100 g/L at 25°C), and a Log Pow of 0.24 (at 25°C), enabling it in generally to be absorbed through the skin. Hence, the absorption rate of SABOSTAB UV-91 including its toxicologically more relevant hydrolysis product 2,2,6,6-Tetramethylpiperidin-4-ol is most likely in the range of 30%.
Taking into account the medium molecular weight of 395.67 g/mol resp. 423.73 g/mol of the unchanged SABOSTAB UV-91, its lipophilicity and poor water solubility, the absolute systemic bioavailablility is rather low and expected to be more extensive in fat tissues than in other tissues.
Considering the most likely occurring hydrolysis, however, the systemic bioavailability of the hydrolysis products, especially 2,2,6,6-Tetramethylpiperidin-4-ol, is rather high, leading toa certain peak exposure of both the hydrolysis products and their metabolites. Due to the high water solubility of 2,2,6,6-Tetramethylpiperidin-4-ol and the furthermore expected high solubility of the metabolites because of their hydroxyl groups, a rapid distribution in the aqueous compartments of the body is expected as well as a rapid excretion.
Since SABOSTAB UV-91 is not considered hydrolytically stable, a prolonged, extensive accumulation is not expected. After metabolism, the excretion of the metabolites, either as such or after Phase 2 metabolism, will occur rather fast, as well as the unchanged hydrolysis products and their metabolites would, an accumulation is not very likely, too.
Since an at least partial hydrolysis of the ether bonds may occur in the acidic, aqueous environment of the stomach, metabolism of the hydrolysis products is a relevant issue to be considered. Besides Amine hydroxylation and Aliphatic hydroxylation of the parent compound being subject to further hydrolysis, the most like metabolizing processes for 2,2,6,6-Tetramethylpiperidin-4-ol were identified byToxtree estimation asAmine hydroxylation, Alcohol oxidation (resulting in2,2,6,6-Tetramethyl-4-piperidone) and Aliphatic hydroxylation. In general, it is hence unlikely that the parent substance will be excreted unchanged, the metabolites however will, based on the relevant available functional groups, i.e. ketone or hydroxyl groups, be excreted rather fast either unchanged or as Phase 2 conjugated metabolites via the urine.
In conclusion, SABOSTAB UV-91 has a minor potential for bioaccumulation in its non-metabolized form, and will be excreted rapidly after hydrolysis and accompanying / subsequent metabolism.
The present expert statement covers all relevant toxicokinetic parameters to assess the behaviour of 'Reaction mass of 2,2,6,6-tetramethylpiperidin-4-yl-hexadecanoate and 2,2,6,6-tetramethylpiperidin-4-yl-octadecanoate' in the body, the available information is well-investigated and sufficient to enable one to perform a proper risk assessment. The tonnage-driven data requirement under REACH are fully met and hence, no further information needs to be gathered and further studies can be omitted due to animal welfare.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.